ClinicalTrials.gg
RecruitingNCT06274008Updated Feb 23, 2024

Exparel vs. ACB With Bupivacaine for ACL Reconstruction

A Phase 1 interventional study of Exparel in ACL Tear, Opioid Misuse and Pain, sponsored by Children's Hospital of Orange County. Recruiting at 1 site in United States. Open to participants aged 7 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Children's Hospital of Orange County · Phase 1, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States — 44 open to participants now, 62 under way, 3 of them phase 3. Anterior Cruciate Ligament Injuries · United States.

Planned enrollment
37th of 152
96 · median 50
Started
2023
with 11 others
Phase 1
5 of 176
3 open now
Primary completion
2024-10
later than 5 of 61 live
Registered
144th of 176
by date

Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, this one is the 37th largest by planned enrollment of the 152 interventional ones that give a count, is one of 12 that started in 2023, is one of 5 in phase 1, reaches primary completion later than 5 of the 61 other live ones, and was the 144th registered.

Anterior Cruciate Ligament Injuries

627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

Browse Anterior Cruciate Ligament Injuries studies →

Open to participants now

44 of the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, or all of them as a file.
02

Study summary

Opioid misuse and addiction among children and adolescents is an increasingly concerning problem. Post-surgical opioid prescriptions for commonly performed surgeries such as anterior cruciate ligament reconstruction (ACLR) increase opioid exposure in young athletes. The purpose of the current study is to determine if extended-release Bupivacaine Liposome Injectable Suspension (Exparel) is effective in decreasing at home narcotic consumption compared to standard Bupivacaine Adductor Canal Block for Anterior Cruciate Ligament (ACL) reconstruction/reconstruction for the surgical treatment of adolescents with ACL tears and concomitant pathology i.e. meniscus / cartilage injury/tear.

Read the detailed description

Approximately 13% of high school seniors have reported nonmedical use of prescription opioids in their lifetimes with 8.7% to 11% reporting use within the last year. The second most common source of opioids (36.9%) in this population is leftover medication from previous legitimate prescriptions after injury or procedures. Before injury or surgery, most children and adolescents are narcotic naive. Medical use of opioids in this population increases the risk for nonmedical opioid misuse after high school by 33% (1). As orthopaedic surgeons, the surgeons are in a powerful position to understand and affect change in the adolescent population through patient/parent education and through controlling the amount and type of pain medications prescribed. The investigators propose a Double Blinded RCT of adolescents with ACL +/- meniscus tear to either bupivacaine ACB or Bupivacaine Liposome Injectable Suspension ACB (Exparel) to test whether injectable suspension reduces at home narcotic consumption postoperatively. Currently there is limited data available for the pediatric population and no known randomized controlled trials. Bupivacaine Liposome Injectable Suspension is FDA approved for use in adults but has been used in this pediatric population off-label for many years. Exparel is now FDA approved and indicated for single-dose infiltration in patients aged 6 years and older to produce postsurgical local analgesia. While widely used in the settings of a regional block in adolescents undergoing ACL reconstruction and other surgeries, it does not have specific FDA approval for the use in blocks. This is not uncommon practice and in fact many of the drugs used in pediatrics do not have specific approval by the FDA(2).

After enrollment, the research subject will be randomized into one of two arms and the anesthesiologist will be notified of the arm. Data will be collected at baseline, on day of surgery, and on days 1 through 14 postoperatively. Participants will be instructed to wear Actigraphs in the days leading up to surgery to obtain baseline sleep activity data.

03

Conditions studied

04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are 7-17 years old undergoing elective ACL reconstruction/repair with (ASA) Classification 1-2 at Children's Hospital of Orange County (CHOC).
  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Surgery scheduled between the hours of 8am - 4pm

Exclusion criteria

Exclusion Criteria:

  • No prior major surgery (e.g. transplant procedures, cardiac, cranial surgeries)
  • Learning disability or developmental delay. Learning disability or developmental delay will have been assessed by an outside specialist. Diagnosis will have either been communicated to attending physician by the patient or will be located in patient's medical record. Anything that would impede survey completion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Exparel

    Adductor Canal Block with Bupivacaine Liposome Injectable Suspension Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20

    Drug: Exparel

  • No intervention
    Standard ACB with bupivacaine

    Standard Adductor Canal Block (ACB) with Bupivacaine Standardized amount of 0.5% bupivacaine 20 cc

Interventions

06

What researchers measure

Primary outcomes

  1. At-home narcotic consumption by the patients as measured by the medication form completed by parents post discharge

    Amount administered

    Time frame: Postoperative days 1-3, 7, and 14.

Secondary outcomes

  1. Postoperative pain level of child

    Reported by parent and child via Visual Analogue Scale (VAS). Scores range from 0-100 with higher scores indicating more pain.

    Time frame: Postoperative days 1-3, 7, and 14.

  2. Functional disability of child

    The functional disability inventory is a measure of the degree to which children experience difficulty in physical and psychosocial functioning due to their physical health status. Respondents are asked to rate how much physical difficulty was perceived for a variety of everyday activities. Total scores are computed by summing the ratings for each item. Scores range from 0-60 with higher scores indicating greater perceived functional disability.

    Time frame: Baseline, Postoperative days 1-3, 7, and 14.

  3. Parent and child anxiety

    The state questionnaire contains a 20-item, 4-point self-report rating scale for measuring anxiety. Total scores for situational anxiety range from 20 to 80; higher scores indicate higher levels of anxiety.

    Time frame: Baseline, Postoperative days 1-3, 7, and 14.

  4. Child pain

    The Parent's Postoperative Pain Measure is a 15-item measure to assess child's postoperative pain. Each item refers to an easily identifiable and specific behavior. Items are summed to yield a total score out of 15. A cutoff score of 6 identifies children who have clinically significant pain with excellent sensitivity and specificity.

    Time frame: Postoperative days 1-3, 7, and 14.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • McCabe SE, West BT, Boyd CJ. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. J Adolesc Health. 2013 Apr;52(4):480-5. doi: 10.1016/j.jadohealth.2012.08.007. Epub 2012 Nov 22. PubMed 23298996 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Oct 2024, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Feb 23, 2024
StartActual
Oct 12, 2023
Primary completionEst.
Oct 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06274008
Lead sponsor
Children's Hospital of Orange County
Responsible party
John Schlechter (Principal Investigator, Children's Hospital of Orange County) — Principal investigator
First posted
Feb 23, 2024
Start date
Oct 12, 2023
Primary completion
Oct 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Feb 23, 2024

Study contacts

Haydee Cortes
Contact
haydee.cortes@choc.org
714-456-2837
Kiran Athreya
Contact
kiran.athreya@choc.org
949-306-4857

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion